Comparison of different strategies in prenatal screening for Down's syndrome: Cost effectiveness analysis of computer simulation

BMJ (Online)

Volumn 338, Issue 7692, 2009, Pages 453-456

  Gekas, Jean ^a,b,c   Gagné, Geneviève ^b   Bujold, Emmanuel ^b   Douillard, Daniel ^b   Forest, Jean Claude ^b   Reinharz, Daniel ^b   Rousseau, François ^b  

^a Prenatal Diegnosis Unit   (Canada)

^b Université Laval   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMNIOCENTESIS; ARTICLE; CHORION VILLUS SAMPLING; COMPUTER SIMULATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DOWN SYNDROME; FEMALE; HEALTH CARE COST; HUMAN; PREGNANCY TERMINATION; PRENATAL CARE; PRENATAL SCREENING; PRIORITY JOURNAL; RISK ASSESSMENT; SPONTANEOUS ABORTION;

ABORTION, INDUCED; ADULT; AGE DISTRIBUTION; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DOWN SYNDROME; FEMALE; HEALTH SERVICES MISUSE; HUMANS; MATERNAL AGE; MIDDLE AGED; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; QUEBEC; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 61849085113     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b138     Document Type: Article

References (57)

1. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 1999;341:461-7.
2. Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K, et al. First-trimester screening for trisomies 21 and 18. N Engl J Med 2003;349:1405-13.
3. Roizen NJ, Patterson D. Down's syndrome. Lancet 2003;361:1281-9.
4. Resta RG. Changing demographics of advanced maternal age (AMA) and the impact on the predicted incidence of Down syndrome in the United States: implications for prenatal screening and genetic counseling. Am J Med Genet A 2005;133:31-6.
5. Wyatt P. Integrated, sequential, and contingent screening for Down syndrome - local needs should drive methodology. Prenat Diagn 2007;27:186-7.
6. Ball RH, Caughey AB, Malone FD, Nyberg DA, Comstock CH, Saade GR, et al. First- and second-trimester evaluation of risk for Down syndrome. Obstet Gynecol 2007;110:10-7.
7. Reddy UM, Wapner RJ. Comparison of first and second trimester aneuploidy risk assessment. Clin Obstet Gynecol 2007;50:442-53.
8. Reddy UM. The evolving prenatal screening scene. Obstet Gynecol 2007;110:2-4.
9. Wald NJ, Rudnicka AR, Bestwick JP. Sequential and contingent prenatal screening for Down syndrome. Prenat Diagn 2006;26:769-77.
10. Platt LD, Greene N, Johnson A, Zachary J, Thom E, Krantz D, et al. Sequential pathways of testing after first-trimester screening for trisomy 21. Obstet Gynecol 2004;104:661-6.
11. Benn P, Wright D, Cuckle H. Practical strategies in contingent sequential screening for Down syndrome. Prenat Diagn 2005;25:645-52.
12. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005;353:2001-11.
13. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003;10:56-104.
14. Palomaki GE, Steinort K, Knight GJ, Haddow JE. Comparing three screening strategies for combining first- and second-trimester Down syndrome markers. Obstet Gynecol 2006;107(2 Pt 1):367-75.
15. Kotaska A. Prenatal screening for fetal aneuploidy. J Obstet Gynaecol Can 2007;29:499-500.
16. Summers AM, Langlois S, Wyatt P, Wilson RD. Prenatal screening for fetal aneuploidy. J Obstet Gynaecol Can 2007;29:146-79.
17. Caughey AB. Cost-effectiveness analysis of prenatal diagnosis: methodological issues and concerns. Gynecol Obstet Invest 2005;60:11-8.
18. Biggio JR Jr, Morris TC, Owen J, Stringer JS. An outcomes analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years. Am J Obstet Gynecol 2004;190:721-9.
19. Boulware LE. Challenges for public campaigns to improve the health of persons at high risk of developing CKD. Am J Kidney Dis 2008;51:535-8.
20. Antenatal diagnosis. Report of a consensus development conference. Bethesda, MD: National Institutes of Health, 1979. (NIH Publication No 79-1973.)
21. Haute Autorité de Santé. Évaluation des stratégies de dépistage de la trisomie 21. Recommandation en santé publique Juin 2007.www.has-sante.fr/portail/upload/docs/ application/pdf/synthese-evaluation-des-strategies-de-depistage-de-la-trisomie- 21.pdf.
22. AETMIS. Le dépistage prénatal du syndrome de Down et d'autres aneuploìdes au premier trimestre de la grossesse. 2003. (AETMIS 03-01) xxi:84. www.aetmis.gouv.qc.ca/site/416.262.0.0.1.0.phtml
23. MSSS. Recensement de 2001. Institut de la Statistique du Québec, 2007. www.stat.gouv.qc.ca
24. Morris JK, Mutton DE, Alberman E. Revised estimates of the maternal age specific live birth prevalence of Down's syndrome. J Med Screen 2002;9:2-6.
25. Morris J, Mutton D, Alberman E. Corrections to maternal age-specific live birth prevalence of Down's syndrome. J Med Screen 2005;12:202.
26. Snijders RJ, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. Maternal age- and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol 1999;13:167-70.
27. Snijders R. Fetal loss in Down syndrome pregnancies. Prenat Diagn 1999;19:1180.
28. Forest J-C, Blouin D, Cartier L, Désilets V, Framarin A, Lemyre E, et al. Rapport du comité d'experts sur le dépistage prénatal du syndrome de Down et autres aneuploîdies. Québec: CHUQ-CHUL, AÉTMIS, MSSS, CHUS, CUSM, 2004.
29. MSSS. Banque de données APR-DRG (All Patient Refined Diagnosis Related Groups): Ministère de la Santé et des Services Sociaux du Québec, 2003.
30. MSSS. SIFO Système d'Information Financière et Opérationnelle: méthodologie. Quebec: Direction de la gestion de l'information, Ministère de la Santé et des Services Sociaux (MSSS), 2005.
31. MSSS. Laboratoire de biologie médicale, Mesure de la production Edition 2006-2007. Quebec: La Direction des communications, Ministère de la Santé et des Services Sociaux (MSSS), 2007.
32. RAMQ. Manuel des médecins spécialistes. Quebec: Régie de l'assurance maladie du Québec (RAMQ), Direction des services à la clientèle professionnelle, 2005:607.
33. RAMQ. Manuel des médecins spécialistes de laboratoires en établissement. Quebec: Régie de l'assurance maladie du Québec (RAMQ), Direction des services à la clientèle professionnelle, 2007:176.
34. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005:1-396.
35. Hoover SV, Perry RF. Simulation: a problem-solving approach. London: Addison Wesley, 1989.
36. Bishop AJ, Marteau TM, Armstrong D, Chitty LS, Longworth L, Buxton MJ, et al. Women and health care professionals' preferences for Down's syndrome screening tests: a conjoint analysis study. BJOG 2004;111:775-9.
37. Carroll JC, Reid AJ, Woodward CA, Permaul-Woods JA, Domb S, Ryan G, et al. Ontario Maternal Serum Screening Program: practices, knowledge and opinions of health care providers. CMAJ 1997;156:775-84.
38. Mulvey S, Zachariah R, McIlwaine K, Wallace EM. Do women prefer to have screening tests for Down syndrome that have the lowest screen-positive rate or the highest detection rate? Prenat Diagn 2003;23:828-32.
39. Spencer K, Aitken D. Factors affecting women's preference for type of prenatal screening test for chromosomal anomalies. Ultrasound Obstet Gynecol 2004;24:735-9.
40. Asch A. Prenatal diagnosis and selective abortion: a challenge to practice and policy. Am J Public Health 1999;89:1649-57.
41. Kuppermann M, Feeny D, Gates E, Posner SF, Blumberg B, Washington AE. Preferences of women facing a prenatal diagnostic choice: long-term outcomes matter most. Prenat Diagn 1999;19:711-6.
42. Kuppermann M, Goldberg JD, Nease RF Jr, Washington AE. Who should be offered prenatal diagnosis? The 35-year-old question. Am J Public Health 1999;89:160-3.
43. Cuckle HS. Effect of maternal age curve on the predicted detection rate in maternal serum screening for Down syndrome. Prenat Diagn 1998;18:1127-30.
44. Harris RA, Washington AE, Nease RF Jr, Kuppermann M. Cost utility of prenatal diagnosis and the risk-based threshold. Lancet 2004;363:276-82.
45. Petrou S, Mugford M. Should prenatal diagnostic testing be offered to all pregnant women on economic grounds? Lancet 2004;363:258-9.
46. Caughey AB, Kuppermann M, Norton ME, Washington AE. Nuchal translucency and first trimester biochemical markers for down syndrome screening: a cost-effectiveness analysis. Am J Obstet Gynecol 2002;187:1239-45.
47. Chen Y, Qian X, Li J, Zhang J, Chu A, Schweitzer SO. Cost-effectiveness analysis of prenatal diagnosis intervention for Down's syndrome in China. Int J Technol Assess Health Care 2007;23:138-45.
48. Ritchie K, Bradbury I, Slattery J, Wright D, Iqbal K, Penney G. Economic modelling of antenatal screening and ultrasound scanning programmes for identification of fetal abnormalities. BJOG 2005;112:866-74.
49. Egan JF, Kaminsky LM, DeRoche ME, Barsoom MJ, Borgida AF, Benn PA. Antenatal Down syndrome screening in the United States in 2001: a survey of maternal-fetal medicine specialists. Am J Obstet Gynecol 2002;187:1230-4.
50. Scott A. Nuchal translucency measurement in first trimester Down syndrome screening. Issues Emerg Health Technol 2007;(100):1-6.
51. American College of Obstetricians and Gynecologists. First-trimester screening for fetal aneuploidy: opinion 296. Obstet Gynecol 2004;104:215-7.
52. Gekas J, Gondry J, Mazur S, Cesbron P, Thepot F. Informed consent to serum screening for Down syndrome: are women given adequate information? Prenat Diagn 1999;19:1-7.
53. Lau TK, Leung TN. Genetic screening and diagnosis. Curr Opin Obstet Gynecol 2005;17:163-9.
54. Jackson L. Fetal cells and DNA in maternal blood. Prenat Diagn 2003;23:837-46.
55. Morris JK, Wald NJ, Watt HC. Fetal loss in Down syndrome pregnancies. Prenat Diagn 1999;19:142-5.
56. Sundberg K, Bang J, Smidt-Jensen S, Brocks V, Lundsteen C, Parner J, et al. Randomised study of risk of fetal loss related to early amniocentesis versus chorionic villus sampling. Lancet 1997;350:697-703.
57. CETS. Les enjeux du dépistage et du diagnostic prénatals du syndrome de Down. 1999;(CETS 99-4 RF) xviii:92.